This protein belongs to a family of receptors whose principal member is EGFr (epidermal growth factor receptor) also known as c-erbB1. This family is made up of four members (c-erbB1, c-erbB2, c-erbB3 and c-erbB4) that share great internal homology. Due to this homology, antibodies targeted against this family of proteins can cross react with other members.
It is clinically shown that between 15 and 30% of breast cancers over express the c-erbB2 protein. This over expression implies a worse prognosis for these tumors meaning that they are more aggressive and resistant to Trastuzumab (Herceptin). The detection of messenger RNA for this protein offers multiple advantages as it eliminates the potential for the cross reaction seen in IHC, as well as the potential for incomplete amplified genes transcription in FISH.
As there are therapeutic monoclonal antibodies against this protein is it vital to know if a concrete tumoral case over expresses the c-erbB2 protein or not.
Until now the methods of detection have been based on immunohistochemistry with antibodies targeted against the c-erbB2 protein
which generally yield confusing results and the determination of amplification of the gene that codes for this product.
Cenbimo has designed a probe for in situ hybridization that detects the transcribed RNA of the c-erbB2 gene.
The detection of messenger RNA for this protein offers multiple advantages as it eliminates the confusing aspects of immunohistochemistry, and on the other hand detects real transcription, as to see genetic amplification by FISH does not guarantee that all
amplified genes are transcribing.
Histosonda c-erbB2 consists of 2 fragments of single-stranded DNA with lengths of 672 and 1143 nucleotides that are targeted against expressed sequences of this gene.
The probe incubation period is only 1 hour and as it is a chromogenic hybridization probe the results can be viewed directly by light microscope.
Intended for research use only (RUO).